vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Revolve Group, Inc.（RVLV）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是Revolve Group, Inc.的1.3倍（$406.6M vs $324.4M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 5.7%，领先54.8%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 10.4%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $-13.3M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 9.5%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Revolve Theatre Company是总部位于英国泰晤士河畔亨利的剧团，专注于创作演出政治题材和莎士比亚系列戏剧作品，由奥利弗·登奇、乔·莫里斯与汤姆·史密斯共同创立运营。
BCRX vs RVLV — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $324.4M |
| 净利润 | $245.8M | $18.6M |
| 毛利率 | 97.7% | 53.3% |
| 营业利润率 | 64.0% | 6.3% |
| 净利率 | 60.5% | 5.7% |
| 营收同比 | 209.1% | 10.4% |
| 净利润同比 | 1017.5% | 50.4% |
| 每股收益（稀释后） | $1.13 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $406.6M | $324.4M | ||
| Q3 25 | $159.4M | $295.6M | ||
| Q2 25 | $163.4M | $309.0M | ||
| Q1 25 | $145.5M | $296.7M | ||
| Q4 24 | $131.5M | $293.7M | ||
| Q3 24 | $117.1M | $283.1M | ||
| Q2 24 | $109.3M | $282.5M | ||
| Q1 24 | $92.8M | $270.6M |
| Q4 25 | $245.8M | $18.6M | ||
| Q3 25 | $12.9M | $21.2M | ||
| Q2 25 | $5.1M | $10.2M | ||
| Q1 25 | $32.0K | $11.8M | ||
| Q4 24 | $-26.8M | $12.3M | ||
| Q3 24 | $-14.0M | $11.0M | ||
| Q2 24 | $-12.7M | $15.4M | ||
| Q1 24 | $-35.4M | $10.9M |
| Q4 25 | 97.7% | 53.3% | ||
| Q3 25 | 98.6% | 54.6% | ||
| Q2 25 | 98.3% | 54.1% | ||
| Q1 25 | 96.9% | 52.0% | ||
| Q4 24 | 95.4% | 52.5% | ||
| Q3 24 | 97.3% | 51.2% | ||
| Q2 24 | 98.4% | 54.0% | ||
| Q1 24 | 98.6% | 52.3% |
| Q4 25 | 64.0% | 6.3% | ||
| Q3 25 | 18.6% | 7.1% | ||
| Q2 25 | 18.2% | 5.8% | ||
| Q1 25 | 14.6% | 5.0% | ||
| Q4 24 | -3.4% | 3.9% | ||
| Q3 24 | 6.6% | 5.0% | ||
| Q2 24 | 8.0% | 5.8% | ||
| Q1 24 | -15.6% | 3.4% |
| Q4 25 | 60.5% | 5.7% | ||
| Q3 25 | 8.1% | 7.2% | ||
| Q2 25 | 3.1% | 3.3% | ||
| Q1 25 | 0.0% | 4.0% | ||
| Q4 24 | -20.4% | 4.2% | ||
| Q3 24 | -12.0% | 3.9% | ||
| Q2 24 | -11.6% | 5.4% | ||
| Q1 24 | -38.1% | 4.0% |
| Q4 25 | $1.13 | $0.27 | ||
| Q3 25 | $0.06 | $0.29 | ||
| Q2 25 | $0.02 | $0.14 | ||
| Q1 25 | $0.00 | $0.16 | ||
| Q4 24 | $-0.13 | $0.18 | ||
| Q3 24 | $-0.07 | $0.15 | ||
| Q2 24 | $-0.06 | $0.21 | ||
| Q1 24 | $-0.17 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $292.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $512.5M |
| 总资产 | $514.2M | $765.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $274.7M | $292.3M | ||
| Q3 25 | $212.9M | $315.4M | ||
| Q2 25 | $260.0M | $310.7M | ||
| Q1 25 | $295.1M | $300.8M | ||
| Q4 24 | $320.9M | $256.6M | ||
| Q3 24 | $96.8M | $252.8M | ||
| Q2 24 | $78.4M | $244.7M | ||
| Q1 24 | $84.3M | $273.4M |
| Q4 25 | $-119.2M | $512.5M | ||
| Q3 25 | $-387.9M | $490.2M | ||
| Q2 25 | $-421.6M | $468.6M | ||
| Q1 25 | $-451.9M | $453.4M | ||
| Q4 24 | $-475.9M | $437.8M | ||
| Q3 24 | $-468.6M | $420.8M | ||
| Q2 24 | $-475.6M | $405.8M | ||
| Q1 24 | $-476.2M | $389.9M |
| Q4 25 | $514.2M | $765.0M | ||
| Q3 25 | $446.4M | $751.3M | ||
| Q2 25 | $457.2M | $722.9M | ||
| Q1 25 | $480.0M | $713.9M | ||
| Q4 24 | $490.4M | $665.5M | ||
| Q3 24 | $491.3M | $670.9M | ||
| Q2 24 | $472.4M | $657.8M | ||
| Q1 24 | $467.9M | $650.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $-10.2M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $-13.3M |
| 自由现金流率自由现金流/营收 | 71.6% | -4.1% |
| 资本支出强度资本支出/营收 | 0.2% | 1.0% |
| 现金转化率经营现金流/净利润 | 1.19× | -0.55× |
| 过去12个月自由现金流最近4个季度 | $344.9M | $48.0M |
8季度趋势，按日历期对齐
| Q4 25 | $292.0M | $-10.2M | ||
| Q3 25 | $41.6M | $11.8M | ||
| Q2 25 | $41.3M | $12.6M | ||
| Q1 25 | $-27.5M | $45.1M | ||
| Q4 24 | $-5.2M | $3.9M | ||
| Q3 24 | $8.2M | $9.1M | ||
| Q2 24 | $-1.4M | $-24.7M | ||
| Q1 24 | $-53.7M | $38.4M |
| Q4 25 | $291.2M | $-13.3M | ||
| Q3 25 | $40.3M | $7.5M | ||
| Q2 25 | $41.1M | $10.4M | ||
| Q1 25 | $-27.7M | $43.4M | ||
| Q4 24 | $-5.9M | $2.1M | ||
| Q3 24 | $8.2M | $8.0M | ||
| Q2 24 | $-1.5M | $-25.7M | ||
| Q1 24 | $-53.9M | $36.7M |
| Q4 25 | 71.6% | -4.1% | ||
| Q3 25 | 25.3% | 2.5% | ||
| Q2 25 | 25.2% | 3.4% | ||
| Q1 25 | -19.0% | 14.6% | ||
| Q4 24 | -4.5% | 0.7% | ||
| Q3 24 | 7.0% | 2.8% | ||
| Q2 24 | -1.4% | -9.1% | ||
| Q1 24 | -58.1% | 13.5% |
| Q4 25 | 0.2% | 1.0% | ||
| Q3 25 | 0.8% | 1.5% | ||
| Q2 25 | 0.1% | 0.7% | ||
| Q1 25 | 0.1% | 0.6% | ||
| Q4 24 | 0.5% | 0.6% | ||
| Q3 24 | 0.1% | 0.4% | ||
| Q2 24 | 0.1% | 0.4% | ||
| Q1 24 | 0.3% | 0.6% |
| Q4 25 | 1.19× | -0.55× | ||
| Q3 25 | 3.23× | 0.56× | ||
| Q2 25 | 8.12× | 1.24× | ||
| Q1 25 | -859.91× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | -1.60× | ||
| Q1 24 | — | 3.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
